A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles Following Single and Multiple Doses and Food Effect of CS12192 Capsules in Healthy Adult Chinese Subjects

The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS12192 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.

开始日期2023-07-20

申办/合作机构

深圳微芯生物科技股份有限公司

CTR20231441 / Completed临床1期

在中国健康成年受试者中，采用随机、双盲、安慰剂对照方法评估CS12192胶囊单次和多次给药后的安全性、耐受性、药代动力学和药效动力学特征及食物影响的I期临床研究

主要目的：①评估中国健康成年受试者单次和多次口服CS12192胶囊后的安全性和耐受性；②评估中国健康成年受试者单次和多次口服CS12192胶囊后的药代动力学（PK）特征；③评估食物对中国健康成年受试者单次口服CS12192胶囊后PK的影响。次要目的：评估中国健康成年受试者单次和多次口服CS12192胶囊后的药效动力学（PD）特征。探索性目的：①探索中国健康成年受试者口服CS12192胶囊后血药浓度与QT/QTc间期的关系；②探索CS12192在中国健康成年受试者中的PK/PD关系；③探索CS12192在人体内代谢物谱。

开始日期2023-07-20

申办/合作机构

成都微芯药业有限公司

[+1]

CTR20201755 / Completed临床1期

评价CS12192胶囊在健康受试者中单次给药的安全耐受性、药代动力学和药效动力学特征的I期临床试验

主要目的：1. 评估中国健康成年受试者单次口服不同剂量CS12192胶囊后的安全耐受性，2. 评估中国健康成年受试者单次口服不同剂量CS12192胶囊后药代动力学（PK）特征。次要目的：评估中国健康成年受试者单次口服不同剂量CS12192胶囊后的药效动力学（PD）特征。

开始日期2020-09-03

申办/合作机构

成都微芯药业有限公司

[+1]

100 项与 CS-12192 相关的临床结果

登录后查看更多信息

100 项与 CS-12192 相关的转化医学

登录后查看更多信息

100 项与 CS-12192 相关的专利（医药）

登录后查看更多信息

项与 CS-12192 相关的文献（医药）

2024-08-01·TRANSPLANT IMMUNOLOGY

CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation

Article

作者: Zhou, You ; Yang, Qianjiao ; Shan, Song ; Li, Lingjie ; Huang, Shengjian

BACKGROUND:

Despite the significant role of JAK3 in various autoimmune diseases, including graft-versus-host disease (GVHD), there has been a lack of potent and selective JAK3 inhibitors specifically studied for GVHD. In our preclinical investigations, we evaluated a novel JAK3 inhibitor called CS12192, which is already undergoing clinical investigation in autoimmune diseases.

METHODS:

We evaluated the efficacy of CS12192 in GVHD through mixed lymphocyte reaction (MLR) in both mouse and human cells, as well as allogeneic bone marrow transplantation (BMT) in a murine model.

RESULTS:

CS12192, starting at a concentration of 0.5 μM, dose-dependently reduced the intracellular positivity for cytokines TNF-α and IFN-γ in CD4+ T cells (p < 0.05 to p < 0.0001) and CD8+ T cells (p < 0.01 to p < 0.0001) during mouse allogeneic MLR assays. This effect was observed for both single and double positivity of the cytokines. Moreover, In MLR assays with three different human donors, CS12192 also demonstrated a dose-dependent reduction in the proportion of IFN-γ positive CD4+ T cells (p < 0.0001) and CD8+ T cells (p < 0.01 to p < 0.0001). Additionally, it suppressed T cell proliferation in the mouse MLR (p < 0.05 to p < 0.0001), but this effect was observed in only one human donor (p < 0.001 to p < 0.0001). Furthermore, the administration of CS12192 at 40 and 80 mg/kg BID significantly improved the survival rate in the BMT model, resulting in cumulative 62-day survival rates of 88.89% (p < 0.01) and 100% (p < 0.001), respectively, compared with prednisolone (p < 0.05).

CONCLUSIONS:

CS12192 is a novel, potent and selective JAK3 inhibitor demonstrating great potential to mitigate acute GVHD.

2024-07-03·IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models

Article

作者: Li, Dan ; Pan, Desi ; Zhao, Yiru ; Huang, Shengjian ; Shan, Song ; Mao, Xuhua ; Xiong, Qiuyun ; Chen, Beizhong

OBJECTIVE:

Autoimmune dermatosis (AID) occurs when the body's immune system attacks skin or tissue, leading to various types of skin disorders or injuries. Recent studies show that Janus kinases (JAKs) play critical roles in autoimmune diseases including AID by regulating multiple cytokine signaling pathways. CS12192, a novel JAK3/JAK1/TBK1 inhibitor, has been reported to exert ameliorative effects in rheumatoid arthritis. However, the efficacy of CS12192 on AID is undetermined. This study aims to investigate the therapeutic efficacy of CS12192 on psoriasis (PSO), systemic lupus erythematosus (SLE) and atopic dermatitis (AD) in mouse models.

METHODS:

Interleukin-23 (IL-23)-induced PSO model, spontaneous SLE model of MRL/MpJ-Faslpr/J (MRL/lpr) mice, and oxazolone (OXA) and dinitrochlorobenzene (DNCB)-induced murine AD models were used for the evaluation of curative effects of CS12192, respectively. The skin lesion, biochemical parameters, ear thickness, ear weight and histopathology were assessed accordingly.

RESULTS:

In PSO model, mice treated with CS12192 show reduced ear thickness and ear weight as compared with vehicle. In SLE model, CS12192 ameliorates cutaneous parameters such as lymphadenectasis and skin lesion but not systematic parameters such as proteinuria concentration and score, serum dsDNA and BUN concentration. In AD models, CS12192 dose-dependently improves ear swelling and reduces histological scores, exerting equivalent efficacy with baricitinib, a marketed JAK1/JAK2 inhibitor.

CONCLUSION:

Our findings suggest that the novel JAK3/JAK1/TBK1 inhibitor CS12192 is potentially to alleviate autoimmune dermatosis.

2019-12-01·International immunopharmacology2区 · 医学

Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis

2区 · 医学

Article

作者: Zhang, Yu ; Yang, Qianjiao ; Yu, Jindi ; Zhou, You ; Li, Lingjie ; Pan, Desi ; Li, Zhibin ; Huang, Shengjian ; Lu, Xianping ; Ning, Zhiqiang ; Shan, Song ; Wang, Yanan ; Zhu, Jingzhong ; Xin, Lijun

Rheumatoid arthritis (RA) is a representative autoimmune disease characterized by chronic inflammation and joint destruction. Although biological inhibitors such as TNF-α and IL-6 antibodies have achieved success in clinical therapy, small molecule inhibitors against the Janus kinases (JAKs) involved in the signaling pathways of various cytokine receptors have gained more attraction as safe and efficacious options. In this study, we identified CS12192 as a novel selective JAK3/JAK1/TBK1 inhibitor and investigated its pharmacological effects on the experimental arthritis models in rat and mouse. We found that CS12192 showed a more selective inhibitory activity on JAK3, and to a less extent on JAK1 and TBK1, that were verified by decreased activation of p-STATs and p-IRF3 as well as down-regulation of IFN gene expression in the cultured cells with relevant stimuli. Furthermore, oral treatment with CS12192 dose-dependently ameliorated the disease severity, hind paw swelling, body weight loss, and bone destruction in rat models of adjuvant-induced arthritis (AIA) and collagen-induced arthritis (CIA). In a mouse CIA model, CS12192 also attenuated the disease severity, which was correlated with the suppressed CD4⁺ T cell activation and Th17 function, as well as the reduced cytokine levels in sera and pro-inflammatory cytokine and chemokine gene expression in joint tissue. Corroboratively, RANKL-induced osteoclast formation was inhibited by CS12192. Thus, these results suggest that CS12192 as a novel selective JAK inhibitor has therapeutic potential for the treatment of RA and may provide a new strategy for the control of autoimmune diseases.

项与 CS-12192 相关的新闻（医药）

2024-03-20

·美通社

西格列他钠单药治疗非酒精性脂肪性肝炎的II期临床试验（CGZ203研究）达成首要疗效终点

2024年3月18日，深圳微芯生物科技股份有限公司（以下简称"微芯生物"，股票代码：688321.SH）宣布，西格列他钠单药治疗非酒精性脂肪性肝炎（NASH）的II期临床试验（CGZ203研究）于2024年2月22日顺利完成了数据清理并锁库，试验首要疗效终点达成，进一步的数据分析工作正在进行中。中国普通人群的非酒精性脂肪性肝病（NAFLD）或代谢相关脂肪性肝病（MAFLD）发生率超过25%，其中约25%会进展为NASH，在代谢综合征患者中这一比例更高，全球目前仅有一款甲状腺激素受体β（TRβ）激动剂药物获批用于治疗NASH。 CGZ203研究是一项随机、双盲、安慰剂平行对照、多中心II期临床试验，旨在评价西格列他钠单药针对NASH人群的安全性和初步有效性。CGZ203研究由首都医科大学附属北京友谊医院牵头，在全国24家临床中心开展。初步结果显示，在试验设定的首要疗效终点（18周治疗后经MRI-PDFF评估的肝脂肪含量相比基线的变化比例）上，相比安慰剂对照，西格列他钠两个剂量组均具有统计学显著意义且剂量依赖的降低；在次要疗效终点如肝脂肪含量下降超过30%的患者比例、肝细胞损伤、炎症和纤维化等无创性指标上，西格列他钠两个剂量也具有统计学显著意义的或剂量依赖趋势性的改善。试验总体安全性良好。西格列他钠（双洛平®）是微芯生物独家发现的具有全球专利保护的新分子实体药物，是过氧化物酶增殖体活化相关受体（PPAR）全激动剂，2021年10月在中国获批用于运动饮食无法有效控制的2型糖尿病患者的临床治疗，也是全球首个获批的PPAR全激动剂药物。西格列他钠在国内还完成了联合二甲双胍治疗二甲双胍单药控制不佳的2型糖尿病患者的III期试验（RECAM研究）以及本次针对NASH人群的II期临床试验（CGZ203）。 CGZ203是一项在NASH患者中开展治疗的无创性临床II期探索研究，试验设计为随机、双盲、安慰剂对照的多中心临床试验，入组患者为临床诊断的非酒精性脂肪性肝炎并伴有肝纤维化，按照2:2:1的比例随机入组分别接受每天一次口服西格列他钠48 mg、64 mg和安慰剂治疗，治疗周期为18周。试验的首要疗效终点为治疗18周后经磁共振质子密度脂肪分数（MRI-PDFF）评估的肝脏脂肪含量（LFC）相比基线变化的比例，次要终点包括LFC变化的绝对值、LFC下降超过30%的人群比例、其它肝细胞损伤、炎症、纤维化无创性指标的变化，同时观察评估试验期间患者的安全性。微芯生物是由资深留美归国团队于2001年创立的现代生物医药企业。公司专长于原创新分子实体药物研发，致力于为患者提供价格可承受的、临床亟需的、具有革命性疗效的创新机制药物。凭借自主创建的国际先进的"基于化学基因组学的集成式药物发现及早期评价平台"，微芯生物在肿瘤、代谢性疾病、自身免疫性疾病、中枢神经性疾病等重大疾病领域已开发出包括西达本胺（已上市）、西格列他钠（已上市）、西奥罗尼（临床Ⅲ期）、CS12192(临床Ⅰ期)、CS23546（临床I期）、CS32582（临床I期）在内的多个原创新药产品线。目前，微芯生物拥有以深圳总部/研发中心/GMP生产基地全资子公司深圳微芯药业有限责任公司、成都区域总部/研发中心/创新药生产基地全资子公司成都微芯药业有限公司、北京分公司（临床研究中心）、上海分公司（商业中心）及微芯生物科技（美国）有限公司的全球化产业布局。同时，作为国家首批"创新药物孵化基地"，国家高新技术企业，公司独立承担数十项国家"863"、"十五"、"十一五"、"十二五"及"十三五"国家重大科技专项及"重大新药创制"项目。累计申请境内外发明专利600余项，160余项已获授权。内容来源于网络，如有侵权，请联系删除。

临床3期ASH会议

2024-03-18

·PRNewswire

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024. The primary efficacy endpoint of the trial has been achieved, and further data analysis is currently underway. The incidence of non-alcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) in the general population of China exceeds 25%, of which about 25% will progress to NASH, and this proportion is even higher in patients with metabolic syndrome. Currently, there is only one thyroid receptor β (TRβ) agonist approved worldwide. The CGZ203 study is a randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial aimed to evaluate the safety and preliminary efficacy of chiglitazar monotherapy in diagnosed NASH patients. The CGZ203 study was led by Beijing Friendship Hospital affiliated to Capital Medical University and conducted in 24 clinical sites nationwide. Preliminary results showed that both dose groups of chiglitazar produced significant and dose-dependent reductions at the primary efficacy endpoint (the proportion of changes from baseline in liver fat content evaluated by MRI-PDFF after 18 weeks of treatment), compared to placebo control group. In terms of secondary efficacy endpoints such as the proportion of patients with an over 30% decrease in liver fat content, non-invasive indicators related to hepatocyte damage, inflammation, and fibrosis and so on, both dose groups of chiglitazar also showed significant or dose-dependent trend of improvements. The overall safety is good. The detailed research results will be presented on an upcoming scientific conference or in research article. About Chiglitazar: Chiglitazar (Carfloglitazar) is a novel peroxisome proliferator activation related receptor (PPAR) pan-agonist, independently discovered and developed by Shenzhen chipscreen biosciences with global patent protection. It was firstly approved in China in October 2021, for clinical treatment of type 2 diabetes patients who cannot be effectively controlled by exercise and diet control. It is also the first approved PPAR pan-agonist in the world. Chiglitazar has already completed a phase III trial of combination with metformin to treat type 2 diabetes patients (RECAM study) and the current phase II trial in NASH patients (CGZ203) in China. About CGZ203: CGZ203 is an exploratory phase II trial aimed at treating NASH patients. It was designed as a randomized, double-blind, placebo-controlled multicenter clinical trial. The clinically diagnosed NASH patients were randomly enrolled in a ratio of 2:2:1 to receive oral administration of chiglitazar 48 mg, 64 mg, and placebo once a day respectively, with a treatment period of 18 weeks. The primary efficacy endpoint is the percentage of changes from baseline in liver fat content (LFC) evaluated by magnetic resonance proton density fat fraction (MRI-PDFF) after 18 weeks of treatment. Secondary endpoints include the absolute value of LFC changes, the proportion of people with a decrease of more than 30% in LFC, changes in other non-invasive indicators of liver cell damage, inflammation, and fibrosis, and the patient safety during the trial period. About Chipscreen: Shenzhen Chipscreen biosciences is a modern biopharmaceutical enterprise founded by a senior overseas Returnees team in 2001. The company specializes in the discovery and development of original new molecular entity drugs, focus on five major disease fields of cancer, metabolic diseases, autoimmune diseases, central nervous system diseases. With the independently created "integrated drug discovery and early evaluation platform based on chemical genomics", chipscreen has developed multiple original new drugs including two marketed products Chidamide (Tucidinostat) and Chiglitazar (Carfloglitazar), several clinical stage drug candidates Chiauranib (phase III), CS12192 (phase I), CS23546 (phase I), and CS32582 (Phase I). Till now, chipscreen has established a global industrial layout consisting of its headquarters, R&D center, a wholly-owned subsidiary of GMP production base (Shenzhen chipscreen Pharmaceutical Co., Ltd.) in Shenzhen, a wholly-owned subsidiary of its Chengdu regional headquarters/R&D center/innovative drug production base (Chengdu chipscreen Pharmaceutical Co., Ltd.) in Chengdu, Beijing branch (clinical research center), Shanghai branch (commercial center), and chipscreen Biosciences (USA) Co., Ltd. Chipscreen is one of the first batch of national "innovative drug incubation bases" and a national high-tech enterprise, independently undertakes dozens of national "863", "10th/11th/12th/13th five year plan of major scientific and technological special projects", and "major new drug creation" projects. A total of over 600 domestic and foreign invention patents have been applied, and over 160 have been authorized. SOURCE Shenzhen Chipscreen Biosciences Co., Ltd.

临床2期临床结果上市批准临床3期

2024-03-05

·药渡

利润飙升408.11%！微芯生物“两驾马车”驱动，研发之路高歌猛进

来源：药渡撰文：四月的雨编辑：维他命近日，微芯生物发布了2023年业绩快报。营收方面，报告显示微芯生物2023年度总营收为5.24亿元，同比下降1.19%，营收下滑主要是2023年未发生触及西达本胺在美国授权的里程碑事件，致公司收取美国HUYABIO特许权使用费中的里程碑收益同比减少96.22%。利润方面，微芯生物实现归属于母公司所有者的扣除非经常性损益的净利润为-21749.56万元，同比下降3433.88%。主要原因是报告期内微芯生物持续加大药物研究与临床开发的力度，研发费用投入持续加大。研发投入方面，2023年度微芯生物研发投入40574.39万元，同比增长40.91%，研发费用27134.71万元，同比增长65.79%。让人眼前一亮的是，微芯生物2023年归母净利润为8884.18万元，同比增加408.11%，并且继续增加研发投入，研发资金占比已达到国内药企头部水准。图1. 微芯生物2023年度财报，来源：微芯生物2023年度业绩快报在获批产品并不丰富的情况下，微芯生物如何做到的归母净利润同比增长408.11%？这还要从两驾马车”说起。PART.01“两驾马车”拉动营收快速增长微芯生物能做到利润暴涨408.11%，还要从其产品说起。目前，微芯生物有两款商业化产品，分别为西达本胺和西格列他钠。西达本胺01创国内创新药物license out的先河西达本胺是全球首个亚型选择性组蛋白去乙酰化酶（HDAC）抑制剂和全球首个获批治疗外周T细胞淋巴瘤及晚期激素阳性乳腺癌的口服治疗药物，同时，西达本胺也开创了国内创新药物license out的先河。西达本胺为微芯生物首个商业化产品，该药物于2014年12月23日在国内获批，用于治疗T细胞淋巴瘤。2019年11月，在我国获批乳腺癌适应症。2023年提交了第三个适应症的上市申请，用于治疗弥漫大B细胞淋巴瘤。在日本，西达本胺于2021年6月份获批成人T细胞白血病，于2021年12月份获批外周T细胞淋巴瘤适应症。在中国台湾，2023年3月获批，与依西美坦联用用于治疗乳腺癌。除此以外，西达本胺目前多项适应症处于临床阶段，其中黑色素瘤适应症处于全球多中心临床III期阶段，并且在国内以及国际正在展开多项联合用药的临床试验研究。销售额方面，据微芯生物公布的2023年半年报数据显示，上半年西达本胺销售额为2.28亿元，同比增长17.40%。该药物于2017年7月被纳入国家医保，惠及更多患者。图2. 微芯生物2023年上半年销售收入情况，来源：微芯生物2023年半年度报告西格列他钠02微芯生物首个针对代谢病药物西格列他钠是微芯生物第二款商业化产品。是微芯生物自主研发的全新机制胰岛素增敏剂，用于二型糖尿病及代谢综合征，同时也是全球第一个获批治疗2型糖尿病的PPAR全激动剂。西格列他钠是微芯生物首个针对代谢病的药物。西格列他钠则于2021年10月份上市，用于治疗2型糖尿病，并且于2023年1月纳入2022年国家医保目录。纳入医保后，2023年上半年西格列他钠销售量增长456.26%，但是受单价下降影响，上半年实现销售收入750.77万元，同比增长28.38%。图3. 西格列他钠销售量，来源：微芯生物2023年半年度报告在研适应症方面，联合二甲双胍治疗经二甲双胍单药控制不佳的2型糖尿病的上市申请已获受理，同时NASH适应症已经进行至临床II期阶段。PART.02高研发投入的重磅适应症和重磅单品在研管线研发投入方面一直是微芯生物发展的重点，2023年微芯生物研发投入达40574.39万元，同比增长40.91%；研发费用27134.71万元，同比增长65.79%。高投入换来的是高回报，目前微芯生物有多个管线处于临床阶段。其中，西达本胺目前多个肿瘤适应症均已进行至临床后期阶段。而西格列他钠也开始进军NASH领域，目前处于临床II期阶段。西奥罗尼除此以外，微芯生物在研药物西奥罗尼也是较为值得关注的一款药物，该药物未来也具有成为“重磅炸弹”的潜力，西奥罗尼是一个多靶点多通路选择性激酶抑制剂，属于小分子抗肿瘤原创新药，可选择性抑制AuroraB、CSF1R以及VEGFR/PDGFR/DDR等多个激酶靶点。西奥罗尼是全球首创的“三通路靶向激酶抑制剂”，可同时通过抑制肿瘤血管生成、抑制肿瘤细胞有丝分裂和调节肿瘤微环境，具有成为同类最优的潜力。西奥罗尼目前已经多项适应症研究进入临床II期以及III期阶段。CS12192CS12192是一款具有高选择性JAK3激酶抑制剂，同时部分抑制JAK1和TBK1激酶，在研的适应症为自身免疫性疾病，如类风湿性关节炎、多发性硬化病、系统性红斑狼疮以及银屑病等。与其他JAK激酶抑制剂相比，CS12192既能减少炎症反应发生，还可减轻免疫细胞的组织侵袭，因此具有较好的疗效。该药物目前处于临床I期阶段。CS23546CS23546是一款小分子PD-L1抑制剂，通过结合PD-L1并诱导其内吞从而解除PD-1/PD-L1信号通路介导的免疫抑制活性。据临床前研究显示，CS23546显示出良好的口服吸收和肿瘤组织局部富集的代谢特征，单药针对多种肿瘤均有效果。下表1为微芯生物当前管线情况，涉及多个疾病领域。表1. 微芯生物管线，数据来源：微芯生物官网PART.03接轨国际开创本土药企license out先河2006年，一笔交易令国内企业震惊，微芯生物将西达本胺除中国以外的开发和商业化权利授予HUYABIO，这是国内首个license out，交易总金额达2800万美元。西达本胺的专利授权，让微芯生物成为了首个license out的中国原创药企，向全世界证明了中国医药公司的研发能力。而微芯生物也是借助着这笔资金，熬过了最为困难的时刻。除西达本胺license out外，微芯生物产品管线也与国际接轨。包括西达本胺和西奥罗尼等，都有全球同步的临床试验项目。除此以外，微芯生物积极布局海外专利。据统计，西达本胺已在全球范围内申请发明专利60余项，已获授权20余项。目前，西达本胺的外周T细胞淋巴瘤适应症发明专利保护期持续至2034年，西达本胺的乳腺癌适应症发明专利保护期持续至2038年。小结“两驾马车”带动微芯生物不断前进，而众多的在研管线也将为微芯生物后续的发展提供不竭的动力。除此以外，微芯生物积极加大研发投入，不断注入新鲜血液，未来可期。参考资料：[1]微芯生物财报*声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！盘点：2023年CDE发布药品注册指导原则及法规全景图国内首个「十亿美元分子」诞生记：从零到一→同类最佳→年销售额破十亿美元……鼻腔药物递送全揭秘，优势与挑战知多少？

临床3期引进/卖出财报医药出海

100 项与 CS-12192 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
自身免疫性疾病	临床1期	中国	深圳微芯生物科技股份有限公司	2020-09-03
移植物抗宿主病	临床1期	美国	深圳微芯生物科技股份有限公司	-
类风湿关节炎	临床申请批准	中国	深圳微芯生物科技股份有限公司	2020-06-02
斑秃	临床前	中国	深圳微芯生物科技股份有限公司	2020-12-01
特应性皮炎	临床前	中国	深圳微芯生物科技股份有限公司	2020-12-01
炎症性肠病	临床前	中国	深圳微芯生物科技股份有限公司	2020-12-01
多发性硬化症	临床前	中国	深圳微芯生物科技股份有限公司	2020-12-01
系统性红斑狼疮	临床前	中国	深圳微芯生物科技股份有限公司	2020-12-01